Marksans Pharma (Mid Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Marksans Pharma Limited |
|||
|
Price: ₹252.45 (-2.59%) | ||
| 52 Week Low: ₹130.00 52 Week High: ₹358.70 |
|||
| Market Capital: 14,073 Crore (Midcap) | |||
| Healthcare -> Drug Manufacturers—General | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Marksans Pharma Share Price Target For 2025
- 1.1.1: Marksans Pharma Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Marksans Pharma Share Price Target For 2026
- 1.2.1: Marksans Pharma Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Marksans Pharma Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Marksans Pharma Brief Company Overview
- 4: Marksans Pharma Financial Performance
- 4.0.1: Is Marksans Pharma A Good Buy For Long Term?
Marksans Pharma, a Mid Cap company in the Drug Manufacturers—General Industry has delivered 1314.6% returns in 5-year showing 18.1% quarterly revenue growth with 14.7% profit margin, making it a potential Multibagger.
To predict the Marksans Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Marksans Pharma Share Price Target For 2025
The line chart displays the monthly closing prices of Marksans Pharma with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Marksans Pharma shares in 2025, see the table below.
Marksans Pharma Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 293.2 (+16.14%) | Price Action: 15 Oct 2024 Low |
| 2025 Target 2 | 290.0 (+14.87%) | Price Action: 27 Dec 2024 Low |
| 2025 Target 1 | 286.95 (+13.66%) | Price Action: 11 Oct 2024 Low |
| Current Price | 252.45 | Marksans Pharma's share price as of 22 Jan 2025 |
| Stop Loss 1 | 236.84 (-6.19%) | Price Action: Sep 2024 Low |
| Stop Loss 2 | 232.62 (-7.86%) | Price Action: 27 Aug 2024 Low |
| Stop Loss 3 | 230.13 (-8.85%) | Price Action: 23 Aug 2024 High |
Short-Term Technical Outlook
Current Technical Position: Marksans Pharma is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹281.43 serves as the nearest technical reference point.
Historical Returns: 3-month: -10.53% | 6-month: +23.08% | 1-year: +67.16%
Marksans Pharma Share Price Target For 2026
The line chart displays the monthly closing prices of Marksans Pharma with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Marksans Pharma shares in 2026, see the table below.
Marksans Pharma Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 456.79 (+80.94%) | Price Action: Chart |
| 2026 Target 2 | 448.27 (+77.56%) | Price Action: Chart |
| 2026 Target 1 | 443.83 (+75.8%) | Fibonacci Extension Level 64.90% |
| Current Price | 252.45 | Marksans Pharma's share price as of 22 Jan 2025 |
| Stop Loss 1 | 207.13 (-17.96%) | Price Action: 24 Jul 2024 High |
| Stop Loss 2 | 204.93 (-18.82%) | Price Action: 26 Jul 2024 High |
| Stop Loss 3 | 202.64 (-19.73%) | Price Action: 31 Jul 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Marksans Pharma is currently trading at 53.5% of its 52-week range (₹130 - ₹358.7).
Long-Term Trend Analysis: The stock shows mixed long-term signals, trading near key moving averages.
Long-Term Performance: 1-year: +67.16% | 3-year: +367.78% | 5-year: +1,314.57%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Marksans Pharma Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹252.45 | ||
| 2025 | ₹463.27 | +83.5% | ₹470.22 |
| 2026 | ₹668.28 | +44.25% | ₹678.30 |
| 2027 | ₹955.62 | +42.99% | ₹969.95 |
| 2028 | ₹1,309.24 | +37% | ₹1,328.88 |
| 2029 | ₹1,761.05 | +34.5% | ₹1,787.47 |
| 2030 | ₹2,348.97 | +33.38% | ₹2,384.20 |
| 2031 | ₹3,389.34 | +44.29% | ₹3,440.18 |
| 2032 | ₹4,473.83 | +31.99% | ₹4,540.94 |
| 2033 | ₹6,372.23 | +42.43% | ₹6,467.81 |
| 2034 | ₹8,678.73 | +36.19% | ₹8,808.91 |
| 2035 | ₹11,645.97 | +34.18% | ₹11,820.66 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Marksans Pharma Brief Company Overview
Marksans Pharma Limited: A Versatile Generic Pharmaceutical Giant Established in 1992, Marksans Pharma Limited is a leading pharmaceutical company renowned for its comprehensive product portfolio and global reach. Diverse Product Range: Analgesics ...
Antidiabetics Cardiovascular medications Antibiotics Dermatology products Hormonal therapies Injectables Gastroenterology formulations Global Presence: Headquartered in Mumbai, India, Marksans Pharma Limited markets its products worldwide. Commitment to Quality: The company is dedicated to providing high-quality, affordable generic medications to meet the evolving needs of patients globally.Marksans Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 14,073 Crore | Market valuation of Marksans Pharma's shares. |
| Revenue (TTM) | 2,267.99 Crore | Total revenue generated by Marksans Pharma over the past twelve months. |
| Net Income (TTM) | +333.79 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +18.28% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +14.71% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+18.09% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+29.29% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
11.7 | Company's total debt divided by total shareholder equity. |
| Total Debt | 244.06 Crore | Sum of Marksans Pharma's current & long-term financial obligations. |
| Total Cash | 700.57 Crore | Total amount of liquid funds available to Marksans Pharma. |
| Beta | 1.66 | Beta is greater than 1 indicating that the Marksans Pharma's price is more volatile than the market. |
Is Marksans Pharma A Good Buy For Long Term?
No valid response content found
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
